Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 20, 2007, Pages 8526-8531

  Ying, Chunxiao ^a   Li, Ying ^a,b   Leung, Chung Hang ^a   Robek, Michael D ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 6F Fu Xing Plaza ^*  (China)

Author keywords

HBV promoters; Helioxanthin; Hepatocyte nuclear factors

Indexed keywords

FETOPROTEIN; HELIOXANTHIN DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 3; HEPATOCYTE NUCLEAR FACTOR 4; LAMIVUDINE; NATURAL PRODUCT; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA; XANTHINE DERIVATIVE; 1,3 BENZODIOXOLE DERIVATIVE; 8 1 COMPOUND; 8-1 COMPOUND; ANTIVIRUS AGENT; HELIOXANTHIN; HEPATOCYTE NUCLEAR FACTOR; PHTHALAZINE DERIVATIVE; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESEARCH; HEPATITIS B; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE; BIOLOGICAL MODEL; CELL DEATH; CELL LINE; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; HEPATITIS B VIRUS; METABOLISM; PROMOTER REGION; PROTEIN BINDING; RNA STABILITY; THERMODYNAMICS; TIME;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; BENZODIOXOLES; CELL DEATH; CELL LINE; DNA, VIRAL; DOWN-REGULATION; HEPATITIS B VIRUS; HEPATOCYTE NUCLEAR FACTORS; HUMANS; LAMIVUDINE; MODELS, BIOLOGICAL; PHTHALAZINES; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RNA STABILITY; RNA, VIRAL; THERMODYNAMICS; TIME FACTORS; TRANSCRIPTION, GENETIC; VIRAL PROTEINS; XANTHINES;

EID: 34347223650     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0609883104     Document Type: Article

References (19)

1. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, et al. (2003) Science 299:893-896.
2. Yeo H, Li Y, Fu L, Zhu JL, Gullen EA, Dutschman GE, Lee Y, Chung R, Huang ES, Austin DJ, Cheng YC (2005) J Med Chem 48:534-546.
3. Li Y, Fu L, Yeo H, Zhu JL, Chou CK, Kou YH, Yeh SF, Gullen E, Austin D, Cheng YC (2005) Antivir Chem Chemother 16:193-201.
4. Cheng YC, Ying CX, Leung CH, Li Y (2005) J. Clin Virol 34(Suppl 1):S147-S150.
5. Fu L, Cheng YC (2000) Antimicrob Agents Chemother 44:3402-3407.
6. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV (2002) J Virol 76:5646-5653.
7. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC (1991) Proc Natl Acad Sci USA 88:8495-8499.
8. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV (2005) Proc Natl Acad Sci USA 102:9913-9917.
9. Moolla N, Kew M, Arbuthnot P (2002) J Viral Hepat 9:323-331.
10. Raney AK, Johnson JL, Palmer CN, McLachlan A (1997) J Virol 71:1058-1071.
11. Gilbert S, Galarneau L, Lamontagne A, Roy S, Belanger L (2000) J Virol 74:5032-5039.
12. Guo J-T, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C (2003) J Virol 76:1885-1893.
13. Sund NJ, Ang SL, Sackett SD, Shen W, Daigle N, Magnuson MA, Kaestner KH (2000) Mol Cell Biol 20:5175-5183.
14. Li M, Xie Y, Wu X, Kong Y, Wang Y (1995) Virology 214:371-378.
15. Tang H, McLachlan A (2002) J Virol 76:8572-8581.
16. Watt AJ, Garrison WD, Duncan SA (2003) Hepatology 37:1249-1253.
17. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Mol Cell Biol 21:1393-1403.
18. Kwon JA, Rho HM (2002) Biochem Cell Biol 80:445-455.
19. Dignam JD, Martin PL, Shastry BS, Roeder RG (1983) Methods Enzymol 101:582-698.